Premium Nahrungsergänzungsmittel | artgerecht

Ivabradine – Uses, Mechanism & Side Effects

Ivabradine is a heart medication that reduces heart rate without affecting blood pressure. It is used in chronic heart failure and stable angina pectoris.

Regular tips about health Regular tips about health

Things worth knowing about "Ivabradine"

Ivabradine is a heart medication that reduces heart rate without affecting blood pressure. It is used in chronic heart failure and stable angina pectoris.

What is Ivabradine?

Ivabradine is a heart rate-reducing medication belonging to the class of selective sinus node inhibitors. It is primarily used to treat chronic heart failure and stable angina pectoris (chest pain caused by reduced blood flow to the heart). Unlike many other cardiac medications, ivabradine exclusively reduces heart rate without significantly affecting blood pressure or the contractile strength of the heart muscle.

Indications

Ivabradine is approved for the following conditions:

Chronic heart failure: In patients with reduced left ventricular ejection fraction (LVEF ≤ 35%), sinus rhythm, and a resting heart rate of ≥ 75 beats per minute, used in combination with standard therapy including beta-blockers.
Stable angina pectoris: In adults with coronary artery disease and sinus rhythm when beta-blockers are not tolerated or are contraindicated.

Mechanism of Action

Ivabradine selectively inhibits the If channel (also known as the funny channel) located in the sinus node of the heart. This ion channel controls the pacemaker current and thus determines the spontaneous depolarization rate of sinus node cells. By blocking the If channel, the rate of depolarization is slowed, resulting in a reduction of heart rate. Because this mechanism is specific to the sinus node, blood pressure regulation and myocardial contractility remain unaffected.

Dosage

Dosage of ivabradine is determined individually by the treating physician. General guidelines according to the prescribing information are:

Starting dose: typically 5 mg twice daily (morning and evening with meals).
Adjustment: Depending on tolerability and heart rate, the dose may be increased to 7.5 mg twice daily.
Reduction: If resting heart rate falls below 50 beats per minute, the dose should be reduced to 2.5 mg twice daily or the medication should be discontinued.
Special populations: Caution is advised in elderly patients and those with hepatic impairment.

Side Effects

Ivabradine is generally well tolerated, but may cause the following side effects:

Very common: Luminous phenomena (phosphenes) – perceived flashes of light or bright spots in the visual field, especially with sudden changes in light intensity. These are usually transient and harmless.
Common: Bradycardia (abnormally slow heart rate), blurred vision.
Uncommon: Headache, dizziness, nausea, cardiac arrhythmias (e.g., atrial fibrillation).
Rare: Hypersensitivity reactions, erythema multiforme.

Contraindications

Ivabradine must not be used in patients with:

Resting heart rate below 70 beats per minute before starting treatment
Cardiogenic shock or acute myocardial infarction
Severe hypotension (low blood pressure)
Sick sinus syndrome or second- and third-degree AV block (without a pacemaker)
Severe hepatic insufficiency
Pregnancy and breastfeeding
Concomitant use of strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin)

Drug Interactions

Ivabradine is metabolized in the liver via the enzyme CYP3A4. The following interactions are clinically relevant:

CYP3A4 inhibitors (e.g., itraconazole, verapamil, diltiazem): Increase ivabradine plasma levels and thus the risk of bradycardia.
CYP3A4 inducers (e.g., rifampicin, St. John's wort): Reduce the effectiveness of ivabradine.
Bradycardia-promoting medications (e.g., beta-blockers, digoxin, amiodarone): Increased risk of excessive heart rate reduction.

Treatment Context

Ivabradine is always used as part of a comprehensive cardiac treatment plan and does not replace other heart medications. In heart failure, it is prescribed alongside ACE inhibitors, beta-blockers, and diuretics. In angina pectoris, it serves as an alternative or add-on therapy when beta-blockers are insufficient or not tolerated. Regular heart rate monitoring by the treating physician is required throughout therapy.

References

European Medicines Agency (EMA): Procoralan (Ivabradine) – Product Information and EPAR. www.ema.europa.eu
Ponikowski P et al. – 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2016.
Fox K et al. – Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. The Lancet, 2008.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.